Last reviewed · How we verify
GSK Biologicals' IPV vaccine
GSK Biologicals' IPV vaccine is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Poliomyelitis prevention in infants and children.
IPV vaccine stimulates the immune system to produce antibodies against inactivated poliovirus types 1, 2, and 3, providing protection against poliomyelitis.
IPV vaccine stimulates the immune system to produce antibodies against inactivated poliovirus types 1, 2, and 3, providing protection against poliomyelitis. Used for Poliomyelitis prevention in infants and children.
At a glance
| Generic name | GSK Biologicals' IPV vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Inactivated poliovirus vaccine (IPV) contains chemically inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses without causing disease. The vaccine induces production of neutralizing antibodies against all three poliovirus serotypes, preventing infection and transmission of wild-type poliovirus.
Approved indications
- Poliomyelitis prevention in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine (PHASE3)
- Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. (PHASE3)
- Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (PHASE2)
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' IPV vaccine CI brief — competitive landscape report
- GSK Biologicals' IPV vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' IPV vaccine
What is GSK Biologicals' IPV vaccine?
How does GSK Biologicals' IPV vaccine work?
What is GSK Biologicals' IPV vaccine used for?
Who makes GSK Biologicals' IPV vaccine?
What drug class is GSK Biologicals' IPV vaccine in?
What development phase is GSK Biologicals' IPV vaccine in?
What are the side effects of GSK Biologicals' IPV vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Poliomyelitis prevention in infants and children
- Compare: GSK Biologicals' IPV vaccine vs similar drugs
- Pricing: GSK Biologicals' IPV vaccine cost, discount & access